X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
neurosciences (1148) 1148
science & technology (1146) 1146
life sciences & biomedicine (1083) 1083
humans (966) 966
alzheimer's disease (928) 928
neurosciences & neurology (822) 822
neurovetenskaper (785) 785
neurology (768) 768
cerebrospinal fluid (710) 710
male (700) 700
female (691) 691
aged (613) 613
middle aged (507) 507
biomarkers (506) 506
clinical neurology (505) 505
medical and health sciences (442) 442
medicin och hälsovetenskap (442) 442
biomarkers - cerebrospinal fluid (394) 394
psychiatry (365) 365
alzheimer disease - cerebrospinal fluid (351) 351
neurologi (328) 328
amyloid beta-peptides - cerebrospinal fluid (325) 325
dementia (323) 323
clinical medicine (311) 311
aged, 80 and over (309) 309
klinisk medicin (305) 305
tau proteins - cerebrospinal fluid (288) 288
adult (238) 238
diagnosis (238) 238
peptide fragments - cerebrospinal fluid (237) 237
psykiatri (235) 235
biological markers (208) 208
alzheimer disease - diagnosis (194) 194
alzheimer’s disease (193) 193
brain (192) 192
alzheimer disease (181) 181
tau (173) 173
tau protein (163) 163
mild cognitive impairment (161) 161
neurodegenerative diseases (159) 159
analysis (148) 148
proteins (148) 148
alzheimers disease (147) 147
biomarker (147) 147
research (140) 140
pathology (137) 137
neurodegeneration (128) 128
abridged index medicus (125) 125
mass spectrometry (124) 124
alzheimer disease - genetics (120) 120
cognitive ability (120) 120
amyloid (119) 119
risk factors (116) 116
mental disorders (115) 115
amyloid beta-protein (113) 113
geriatrics & gerontology (113) 113
csf (112) 112
metabolism (108) 108
enzyme-linked immunosorbent assay (107) 107
magnetic resonance imaging (105) 105
alzheimer disease - pathology (103) 103
medical research (103) 103
biomarkers - blood (101) 101
alzheimer disease - metabolism (100) 100
tau proteins (100) 100
cohort studies (99) 99
genetics (94) 94
geriatrics (94) 94
peptides (94) 94
biochemistry & molecular biology (93) 93
physiology (93) 93
phosphorylation (92) 92
physiological aspects (92) 92
basic medicine (90) 90
neuropsychological tests (90) 90
blood (89) 89
brain - pathology (89) 89
plasma (89) 89
medicine, experimental (88) 88
animals (87) 87
disease progression (86) 86
β-amyloid (86) 86
genotype (85) 85
medicine (83) 83
cerebrospinal-fluid (81) 81
testing (81) 81
brain - metabolism (79) 79
case-control studies (79) 79
physics (78) 78
amyloid beta-peptides - metabolism (77) 77
medicinska och farmaceutiska grundvetenskaper (76) 76
investigating or analysing materials by determining theirchemical or physical properties (75) 75
measuring (75) 75
peptide fragments (75) 75
follow-up studies (74) 74
health aspects (74) 74
alzheimers-disease (73) 73
80 and over (72) 72
chemistry (72) 72
longitudinal studies (72) 72
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3183) 3183
French (38) 38
German (21) 21
Swedish (13) 13
Norwegian (8) 8
Spanish (4) 4
Danish (2) 2
Greek (1) 1
Japanese (1) 1
Portuguese (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet neurology, ISSN 1474-4422, 06/2014, Volume 13, Issue 6, pp. 614 - 629
Journal Article
The New England journal of medicine, ISSN 1533-4406, 01/2014, Volume 370, Issue 4, pp. 322 - 333
In two phase 3 trials in patients with Alzheimer's disease, bapineuzumab, a humanized anti–amyloid-beta monoclonal antibody, did not improve clinical outcomes.... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Phosphorylation | Humans | Middle Aged | Male | Positron-Emission Tomography | Treatment Failure | Aged, 80 and over | Amyloid beta-Peptides - cerebrospinal fluid | Female | Severity of Illness Index | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Biomarkers - analysis | Alzheimer Disease - drug therapy | tau Proteins - cerebrospinal fluid | Alzheimer Disease - cerebrospinal fluid | Cognition - drug effects | Neuropsychological Tests | Amyloid beta-Peptides - antagonists & inhibitors | Apolipoproteins E - genetics | Intention to Treat Analysis | Amyloid beta-Peptides - analysis | Brain - pathology | Aged | Biomarkers - cerebrospinal fluid | Edema - chemically induced | Alzheimer Disease - genetics | Monoclonal antibodies | Product development | Research | Drug therapy | Alzheimer's disease | Health aspects | Edema | Nuclear magnetic resonance--NMR | Intravenous administration | Neurodegenerative diseases | Cognitive ability | Clinical trials | Cerebrospinal fluid | Patients | Studies | Tau protein | Apolipoprotein E | Immunotherapy | Alleles | Dementia disorders | Alzheimers disease | Index Medicus | Abridged Index Medicus | Brain | Neurosciences | pathology | Biological Markers | Antibodies | Cognition | tau Proteins | 80 and over | genetics | Amyloid beta-Peptides | Apolipoproteins E | Monoclonal | Neurovetenskaper | drug therapy | chemically induced | Humanized | drug effects | Alzheimer Disease | analysis | antagonists & inhibitors | cerebrospinal fluid | adverse effects | therapeutic use
Journal Article
Neurology and therapy, ISSN 2193-6536, 07/2017, Volume 6, Issue S1, pp. 15 - 24
...Neurol Ther (2017) 6 (Suppl 1):S15–S24 DOI 10.1007/s40120-017-0073-9 REVIEW A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF to Blood Kaj... 
Neurology | Medicine & Public Health | Alzheimer’s disease | Tau protein | Neurogranin | Biomarkers | β-Amyloid | Neurofilament light | Internal Medicine | Cerebrospinal fluid | Alzheimers disease | Measurement techniques
Journal Article